Once-daily gentamicin dosing in pediatric patients without cystic fibrosis. 2010

Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
Department of Pharmacy, Texas Children's Hospital, Houston, Texas 77030, USA.

OBJECTIVE To estimate an appropriate once-daily gentamicin dose and dosing interval for non-critical care pediatric patients older than 3 months of age without cystic fibrosis. METHODS Pharmacokinetic analysis of data from a retrospective medical record review. METHODS Large academic children's hospital. METHODS One hundred fourteen non-critical care pediatric patients older than 3 months of age without cystic fibrosis who received multiple-daily dosing regimens of gentamicin between September 2007 and April 2008. RESULTS Patient-specific pharmacokinetic parameters were calculated using drug concentrations obtained at steady state. Once-daily doses were extrapolated for each patient to achieve goal peak and trough concentrations. Using the average of these doses and the patient-specific pharmacokinetic parameters, theoretical once-daily peak and trough concentrations were calculated for each patient. Patient characteristics were analyzed to determine differences between patients who did and those who did not achieve adequate peak concentrations. Mean +/- SD pharmacokinetic parameters were as follows: elimination rate constant 0.32 +/- 0.06 hour(-1), half-life 2.28 +/- 0.54 hours, and volume of distribution 0.24 +/- 0.08 L/kg. The only patient demographic characteristic found to have a significant effect on the extrapolated peak concentration was age. The following age-specific once-daily doses were calculated: 3 months to less than 2 years, 9.5 mg/kg; 2 years to less than 8 years, 8.5 mg/kg; and 8-18 years, 7 mg/kg. CONCLUSIONS Age was the primary factor in determining the once-daily dose of gentamicin in our pediatric population. Further prospective research is necessary to determine the safety and efficacy of these age-based, once-daily doses for gentamicin.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008499 Medical Records Recording of pertinent information concerning patient's illness or illnesses. Health Diaries,Medical Transcription,Records, Medical,Transcription, Medical,Diaries, Health,Diary, Health,Health Diary,Medical Record,Medical Transcriptions,Record, Medical,Transcriptions, Medical
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
July 1998, Journal of pediatric surgery,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
January 1998, Infectious diseases in obstetrics and gynecology,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
April 2008, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
January 2010, Pharmacotherapy,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
January 1998, The Journal of antimicrobial chemotherapy,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
December 1998, The Pediatric infectious disease journal,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
June 1999, Pediatrics,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
May 2012, Annals of the Academy of Medicine, Singapore,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
June 2014, Therapeutic drug monitoring,
Erin J McDade, and Jeffrey L Wagner, and Brady S Moffett, and Debra L Palazzi
March 2017, The Cochrane database of systematic reviews,
Copied contents to your clipboard!